Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Clinical News

Formation starts Phase I/IIa of AVID100 in solid tumors

Julian Zhu
May 18, 2017 6:39 PM UTC

Formation Biologics Inc. (Austin, Texas) began an open-label, U.S. Phase I/IIa trial of AVID100 in about 80 patients with advanced EGFR-positive solid tumors. Patients will receive escalating doses of IV AVID100 every 3 weeks in the Phase I portion to determine the recommended dose for the Phase IIa portion. The trial is evaluating safety as well as pharmacokinetics, the number of patients with an objective response or stable disease, and duration of response...

Get Unlimited Access
Continue reading with a free trial.
Start a Free TrialLog In
Or Purchase This Article

BCIQ Company Profiles

Forbius